By Fineline Cube Illumina (NASDAQ: ILMN) announced the completion of its acquisition of SomaLogic, a leader in data‑driven proteomics technology, from Standard BioTools. The deal, first announced in June 2025, integrates highly complementary proteomics capabilities, expanding Illumina’s multi‑omics product portfolio and accelerating drug development insights.
Transaction Structure & Deal Terms
| Item | Detail |
|---|---|
| Acquirer | Illumina, Inc. (NASDAQ: ILMN) |
| Target | SomaLogic (from Standard BioTools) |
| Base Purchase Price | USD 350 million in cash |
| Milestone Payments | Up to USD 75 million in near‑term performance milestones |
| Additional Consideration | Performance‑based royalties |
| Payment Terms | Cash payable upon completion, subject to customary adjustments |
| Strategic Rationale | Expand multi‑omics portfolio, integrate proteomics capabilities |
| Technology Focus | Data‑driven proteomics technology |
Strategic Value & Market Impact
- Multi‑Omics Expansion: Acquisition adds large‑scale proteomics capabilities to Illumina’s genomics leadership, creating comprehensive omics solutions
- Drug Development Acceleration: Combined platform enables customers to gain proteomics insights more efficiently, shortening discovery and development timelines
- Market Positioning: Positions Illumina as a leader in integrated multi‑omics, competing with Thermo Fisher, Agilent, and Bruker in proteomics space
- Revenue Synergies: Analysts estimate proteomics market will reach $50 billion : by 2030; SomaLogic acquisition could contribute $500 million : in incremental revenue by 2028
- Technology Integration: SomaLogic’s SOMAmer reagents and assay platforms will be integrated into Illumina’s NextSeq, NovaSeq systems for seamless workflow
- Customer Base: Access to SomaLogic’s biopharma and academic customers expands Illumina’s installed base and recurring consumables revenue
Forward‑Looking Statements
This brief contains forward‑looking statements regarding integration timelines, revenue synergies, and market expansion for Illumina’s proteomics portfolio. Actual results may differ due to integration challenges, competitive responses, and market adoption rates.-Fineline Info & Tech